1. Signaling Pathways
  2. Apoptosis
  3. Bcl-2 Family

Bcl-2 Family (Bcl-2蛋白家族)

Bcl-2 is a family of evolutionarily related proteins. These proteins govern mitochondrial outer membrane permeabilization (MOMP) and can be either pro-apoptotic (Bax, Bad, Bak and Bok among others) or anti-apoptotic (including Bcl-2 proper, Bcl-xL, and Bcl-w, among an assortment of others). There are a total of 25 genes in the Bcl-2 family known to date. Human genes encoding proteins that belong to this family include: Bak1, Bax, Bal-2, Bok, Mcl-1.

Bcl-2 Family 亚型特异性产品:

  • Bcl-2

  • Bcl-xL

  • Bcl-W

  • Mcl-1

  • Bfl-1

  • Bcl-B

  • Bax

  • Bak

  • Bim

目录号 产品名 作用方式 纯度
  • HY-15531
    Venetoclax

    维奈妥拉

    Inhibitor ≥98.0%
    Venetoclax (ABT-199; GDC-0199) 是一种高效,有选择性和口服有效的 Bcl-2 抑制剂,Ki 小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。
  • HY-10087
    Navitoclax

    生根粉263

    Inhibitor ≥98.0%
    Navitoclax (ABT-263) 是有效,可口服的 Bcl-2 抑制剂,可与Bcl-xL,Bcl-2, Bcl-w等多种Bcl-2家族蛋白结合,Ki 值小于 1 nM。
  • HY-100741
    S63845 Inhibitor ≥98.0%
    S63845 是一种有效的选择性骨髓细胞白血病 1 (MCL1) 抑制剂,结合人 MCL1Kd 值为 0.19 nM。
  • HY-19741
    A-1331852 Inhibitor 99.65%
    A-1331852是具有口服活性的BCL-XL选择性抑制剂,Ki值小于10 pM。
  • HY-50907
    ABT-737 Inhibitor 99.72%
    ABT-737 是一种 BH3 模拟物,是一种有效的 Bcl-2Bcl-xLBcl-w 抑制剂,EC50 分别为 30.3 nM、78.7 nM 和 197.8 nM。ABT-737 诱导 BCL-2/BAX 复合物的破坏和 BAK 依赖性但不依赖 BIM 的内在凋亡途径激活。ABT-737 诱导自噬,并且具有用于急性髓系白血病 (AML) 研究的潜力。
  • HY-142209
    ABBV-167 Inhibitor
    ABBV-167 是一种 BCL-2 抑制剂 venetoclax 的磷酸盐前药。
  • HY-138697B
    S65487 hydrochloride Inhibitor 99.67%
    S65487 (VOB560) hydrochloride 是一种有效的选择性 Bcl-2 抑制剂,是 S55746 的前药。S65487 hydrochloride 对 BCL-2 突变也有活性,例如 G101V 和 D103Y。S65487 hydrochloride 对 MCL-1,BFL-1 和 BCL-XL 的亲和力较差。S65487 hydrochloride 诱导细胞凋亡 (apoptosis) 并具有抗癌活性。
  • HY-12908
    Bcl-xL antagonist 2 Antagonist 98.46%
    Bcl-xL antagonist 2 是一种有效的,选择性的,并具有口服活性的 BCL-XL 拮抗剂。IC50Ki 值分别为 0.091 μM和 65 nM。Bcl-xL antagonist 2 可以促进癌细胞凋亡 (apoptosis)。Bcl-xL antagonist 2 有针对研究慢性淋巴细胞白血病 (CLL) 和非霍奇金淋巴瘤 (NHL) 的潜力。
  • HY-101533
    AZD-5991 Inhibitor 99.50%
    AZD-5991 是一种有效的选择性 Mcl-1 抑制剂,FRET 实验检测的 IC50 为 0.7 nM, SPR 实验检测的 Kd 为 0.17 nM。
  • HY-114855
    BT2 Inhibitor 99.56%
    BT2 是 BCKDC 激酶 (BDK) 抑制剂,IC50 值为 3.19 μM。BT2 与 BDK 的结合会触发支链 α-酮酸脱氢酶复合物 (BCKDC) 的 N 末端结构域的螺旋运动,从而导致 BDK 与 BCKDC 分离。BT2 (compound 4) 也是一种有效的选择性的 Mcl-1 抑制剂,Ki 值为 59 μM。
  • HY-19725
    A-1155463 Inhibitor 99.51%
    A-1155463是高效选择性的 BCL-XL 抑制剂,在Molt-4细胞中的EC50值为70 nM。
  • HY-112218
    MIK665 Inhibitor ≥98.0%
    MIK665 (S-64315) ,源于 S63845,是一种髓系细胞白血病序列1 (MCL1) 抑制剂,对 MCL1 的 IC50 为 1.81 nM。
  • HY-101565
    Tapotoclax Inhibitor ≥99.0%
    Tapotoclax (AMG-176) 是一种有效的、有口服活性的、骨髓细胞因子 1 (MCL-1) 的选择性抑制剂,其 Ki 值为 0.13 nM。
  • HY-10969
    Obatoclax Mesylate

    奥巴克拉甲磺酸盐

    Inhibitor ≥98.0%
    Obatoclax Mesylate (GX15-070 Mesylate) 是 BH3 模拟物,是泛 BCL-2 家族蛋白抑制剂,对 BCL-2 的 Ki 值为 220 nM。Obatoclax Mesylate 诱导自噬 (autophagy) 依赖性细胞死亡,并靶向细胞周期蛋白 D1 进行蛋白酶体降解。Obatoclax Mesylate 具有抗癌和广谱抗寄生虫 (antiparasitic) 活性。
  • HY-108705
    BI-3802 Inhibitor 99.43%
    BI-3802 是一种高效的 BCL6 降解剂,能够抑制 BCL6 的Bric-à-brac (BTB) 结构域,IC50 值 ≤3 nM。BI-3802 可诱导 BCL6 蛋白聚集,并促进 E3 连接酶 SIAH1 介导的蛋白降解。BI-3802 具有抗肿瘤活性。
  • HY-15607A
    WEHI-539 hydrochloride Inhibitor 98.31%
    WEHI-539 hydrochloride 是一种选择性的 Bcl-XL 抑制剂,IC50 为 1.1 nM。
  • HY-112416
    AZD4320 Inhibitor 99.10%
    AZD4320 是 BH-3 的新型类似物,有效的 BCL2/BCLxL 的双重抑制剂。AZD4320 对于 KPUM-MS3,KPUM-UH1,和 STR-428 细胞系的 IC50 分别为 26 nM,17 nM,和 170 nM。
  • HY-12048
    Chelerythrine chloride

    盐酸白屈菜红碱

    Inhibitor ≥98.0%
    Chelerythrine chloride 是一种有效,可渗透细胞的蛋白酶 C (protein kinase C) 抑制剂,能够抑制 PKC 活性,IC50 值为 660 nM。Chelerythrine chloride 抑制 Bcl-XL-Bak BH3 肽结合,IC50 为 1.5 μM,并从 Bcl-XL 取代了 Bax。Chelerythrine chloride 诱导细胞凋亡 (apoptosis) 和自噬 (autophagy)。
  • HY-N0674
    Dehydrocorydaline

    脱氢紫堇碱

    Modulator ≥99.0%
    Dehydrocorydaline (13-Methylpalmatine) 是一种生物碱。Dehydrocorydaline 调节 BaxBcl-2 蛋白表达;激活 caspase-7caspase-8,并使 PARP 失活。Dehydrocorydaline 能增强 p38 MAPK 活化,具有抗炎、抗癌等功效。Dehydrocorydaline 具有强大的抗疟疾作用,并具低细胞毒性 (细胞生存力> 90%), P. falciparum 3D7 strain (IC50=38 nM)。
  • HY-P0081
    Bax inhibitor peptide V5 Inhibitor 98.12%
    Bax inhibitor peptide V5 (BIP-V5) 是一种 Bax 诱导凋亡的抑制剂,主要用于癌症研究。
目录号 产品名 / 同用名 种属 表达系统

Bcl-2 family members have been grouped into three classes. The anti-apoptotic subfamily contains the Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B proteins, which suppress apoptosis and contain all four Bcl-2 homology domains, designated BH1-4. The pro-apoptotic subfamily contain BH1-3 domains, such as Bax, Bak, and Bok. A third class of BH3 only proteins Bad, Bid, Bim, Noxa and Puma have a conserved BH3 domain that can bind and regulate the anti-apoptotic BCL-2 proteins to promote apoptosis [1].


The intrinsic pathway is initiated by various signals, principally extracellular stimuli. BH3-only proteins (Bim, Bid, Bad, Noxa, Puma) engage with anti-apoptotic Bcl-2 family proteins to relieve their inhibition of Bax and Bak to activate them. Next, Bax and Bak are oligomerized and activated, leading to mitochondrial outer membrane permeabilization. Once mitochondrial membranes are permeabilized, cytochrome c and/or Smac/DIABLO is released into the cytoplasm, wherein they combine with an adaptor molecule, Apaf-1, and an inactive initiator Caspase, Pro-caspase 9, within a multiprotein complex called the apoptosome. Smac/DIABLO inhibits IAPs to activate Caspase 9. Caspase 9 activates Caspase 3, which is the initiation step for the cascade of Caspase activation. The extrinsic pathway can be activated by cell surface receptors, such as Fas and TNF Receptor, subsequently activating Caspase 8, and leads to Caspase 3 activation and cell demolition. Caspases in turn cleave a series of substrates, activate DNases and orchestrate the demolition of the cell. Bcl-2 family proteins are also found on the endoplasmic reticulum and the perinuclear membrane in hematopoietic cells, but they are predominantly localized to mitochondria [2]

 

Reference:
[1]. Cotter TG, et al. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009 Jul;9(7):501-7.

[2]. Kang MH, et al. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009 Feb 15;15(4):1126-32.

Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.